IL268319A - Benzothiophene estrogen receptor modulators - Google Patents
Benzothiophene estrogen receptor modulatorsInfo
- Publication number
- IL268319A IL268319A IL268319A IL26831919A IL268319A IL 268319 A IL268319 A IL 268319A IL 268319 A IL268319 A IL 268319A IL 26831919 A IL26831919 A IL 26831919A IL 268319 A IL268319 A IL 268319A
- Authority
- IL
- Israel
- Prior art keywords
- estrogen receptor
- receptor modulators
- benzothiophene
- benzothiophene estrogen
- modulators
- Prior art date
Links
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 title 2
- 239000002834 estrogen receptor modulator Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457643P | 2017-02-10 | 2017-02-10 | |
| US201762460358P | 2017-02-17 | 2017-02-17 | |
| US201862614279P | 2018-01-05 | 2018-01-05 | |
| PCT/US2018/017668 WO2018148576A1 (en) | 2017-02-10 | 2018-02-09 | Benzothiophene estrogen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL268319A true IL268319A (en) | 2019-09-26 |
Family
ID=63106724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL268319A IL268319A (en) | 2017-02-10 | 2019-07-29 | Benzothiophene estrogen receptor modulators |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10208011B2 (https=) |
| EP (1) | EP3580223A4 (https=) |
| JP (1) | JP2020507566A (https=) |
| KR (1) | KR20190117582A (https=) |
| CN (1) | CN110461853A (https=) |
| AU (1) | AU2018217809A1 (https=) |
| CA (1) | CA3052810A1 (https=) |
| IL (1) | IL268319A (https=) |
| TW (1) | TW201835064A (https=) |
| WO (1) | WO2018148576A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2968290T3 (da) * | 2013-03-15 | 2019-11-25 | G1 Therapeutics Inc | Transient beskyttelse af normale celler under kemoterapi |
| WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| IL303038B2 (en) | 2016-12-05 | 2024-08-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| EP3565558B1 (en) | 2017-01-06 | 2023-12-06 | G1 Therapeutics, Inc. | Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer |
| EP3749654B1 (en) * | 2018-02-06 | 2025-04-23 | The Board of Trustees of the University of Illinois | Substituted benzothiophene analogs as selective estrogen receptor degraders |
| CN108203404A (zh) * | 2018-03-02 | 2018-06-26 | 上海博邦医药科技有限公司 | (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法 |
| CN112839646A (zh) * | 2018-08-16 | 2021-05-25 | G1治疗公司 | 用于治疗医学疾病的苯并噻吩雌激素受体调节剂 |
| KR20220071223A (ko) | 2019-09-30 | 2022-05-31 | 닛뽕 케미파 가부시키가이샤 | 아제판 유도체 |
| ES3048084T3 (en) | 2020-05-19 | 2025-12-09 | Pharmacosmos Holding As | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| CN113816892A (zh) * | 2021-08-27 | 2021-12-21 | 安徽鼎旺医药有限公司 | 一种醋酸巴多昔芬的合成方法 |
| CN113801094A (zh) * | 2021-10-29 | 2021-12-17 | 中国药科大学 | 一种2-羰基苯并噻吩类化合物及其制备方法和用途 |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU509682B2 (en) | 1975-10-28 | 1980-05-22 | Eli Lilly And Company | 2-Aroyl-3-Phenylbenzothiophene Derivatives |
| US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| EP0146243A1 (en) | 1983-10-31 | 1985-06-26 | Merck Frosst Canada Inc. | Lipoxygenase inhibitors |
| TW366342B (en) | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| US5478847A (en) | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
| EP0752421B1 (en) | 1995-07-07 | 2005-10-12 | AstraZeneca AB | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists |
| US6458811B1 (en) | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
| TW397821B (en) | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
| US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| JP2001519349A (ja) | 1997-10-03 | 2001-10-23 | イーライ・リリー・アンド・カンパニー | ベンゾチオフェン |
| US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
| ID24568A (id) | 1997-11-06 | 2000-07-27 | American Home Prod | Kontrasepsi oral yang mengandung anti-estrogen plus progestin |
| US6060488A (en) * | 1998-09-22 | 2000-05-09 | Eli Lilly And Company | Benzothiophenes for treating estrogen deficiency |
| CO5271696A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
| US7091240B2 (en) | 2000-03-10 | 2006-08-15 | Oxigene, Inc. | Tubulin binding ligands and corresponding prodrug constructs |
| WO2002003989A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating sphincter incontinence |
| EP1990051A1 (en) | 2000-07-06 | 2008-11-12 | Wyeth | Combinations of SSRI and estrogenic agents |
| MXPA02012890A (es) | 2000-07-06 | 2003-10-24 | Wyeth Corp | Uso de compuestos de indol sustituidos para incrementar la actividad de oxido nitrico sintasa. |
| JP2004502731A (ja) | 2000-07-06 | 2004-01-29 | ワイス | スタチン、エストロゲン剤および所望によるエストロゲンの組み合わせ |
| AR030064A1 (es) | 2000-07-06 | 2003-08-13 | Wyeth Corp | Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos |
| MXPA02012897A (es) | 2000-07-06 | 2003-10-24 | Wyeth Corp | Combinaciones de bisfosfonatos, agentes estrigenicos y opcionalmente estrogenos. |
| US20020016318A1 (en) | 2000-07-06 | 2002-02-07 | American Home Products Corporation | Methods of treating breast disorders |
| US6358991B2 (en) | 2000-07-06 | 2002-03-19 | American Home Products Corporation | Methods of treating neuropeptide Y-related conditions |
| AU2001271782A1 (en) | 2000-07-06 | 2002-01-21 | Wyeth | Use of substituted insole compounds for treating excessive intraocular pressure |
| AU2001271784A1 (en) | 2000-07-06 | 2002-01-21 | Wyeth | Therapy for prosthesis-related bone degeneration |
| JP2004507465A (ja) | 2000-08-11 | 2004-03-11 | ワイス | エストロゲン受容体陽性癌腫の治療方法 |
| JP2007502307A (ja) | 2003-08-15 | 2007-02-08 | アストラゼネカ アクチボラグ | グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環 |
| FR2862646B1 (fr) | 2003-11-20 | 2006-02-24 | Merck Sante Sas | Nouveaux composes antidiabetiques contenant des derives benzofuranes, benzothiophenes |
| CA2595477A1 (en) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| US8278290B2 (en) | 2005-02-14 | 2012-10-02 | Biononics Limited | Tubulin polymerisation inhibitors |
| AU2007211840B2 (en) | 2006-02-03 | 2012-03-01 | Bionomics Limited | Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
| CA2656067C (en) | 2006-06-23 | 2014-08-12 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
| EP1947085A1 (en) | 2007-01-19 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Substituted indole sulfonamide compounds, their preparation and use as medicaments |
| EP2183237A1 (en) | 2007-07-25 | 2010-05-12 | F. Hoffmann-Roche AG | Benzofuran- and benzo[b]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators |
| WO2010093578A1 (en) | 2009-02-10 | 2010-08-19 | Glaxo Group Limited | Indolinyl-, benzofuranyl-, and benzothienyl- amides as modulators of chemokine receptors |
| WO2010127452A1 (en) | 2009-05-04 | 2010-11-11 | The Royal Institution For The Advancement Of Learning/Mcgill University | 5-oxo-ete receptor antagonist compounds |
| HUE033581T2 (hu) | 2010-06-10 | 2017-12-28 | Seragon Pharmaceuticals Inc | Ösztrogén receptor modulátorok és alkalmazásaik |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| CA2819299A1 (en) | 2010-12-24 | 2012-06-28 | Merck Sharp & Dohme B.V. | N-substituted azetidine derivatives |
| DE102011087987A1 (de) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| JP6112625B2 (ja) | 2011-12-14 | 2017-04-12 | セラゴン ファーマシューティカルズ，インク． | フッ素化したエストロゲン受容体モジュレーターおよびその使用 |
| PE20150099A1 (es) | 2011-12-16 | 2015-01-30 | Olema Pharmaceuticals Inc | Compuestos novedosos de benzopirano, composiciones y usos de los mismos |
| JP2015505562A (ja) | 2012-01-31 | 2015-02-23 | ノバルティス アーゲー | Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用 |
| SG11201405918XA (en) | 2012-03-20 | 2014-10-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| WO2014066692A1 (en) | 2012-10-24 | 2014-05-01 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating estrogen-related medical disorders |
| EP2912033A4 (en) | 2012-10-24 | 2016-09-14 | Univ Illinois | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-MEDIATED ILLNESSES |
| BR112015018882B1 (pt) * | 2013-02-19 | 2021-09-14 | Novartis Ag | Derivados de benzotiofeno e composições dos mesmos como degradadores de receptor de estrogênio seletivo |
| JP2016517420A (ja) | 2013-03-14 | 2016-06-16 | セラゴン ファーマシューティカルズ， インク． | 多環式エストロゲン受容体モジュレーター及びその使用 |
| TWI653235B (zh) | 2013-05-28 | 2019-03-11 | 阿斯特捷利康公司 | 作為抗癌劑之吲哚衍生物 |
| BR112015030595A2 (pt) | 2013-06-19 | 2017-07-25 | Seragon Pharmaceuticals Inc | moduladores de receptor de estrogênio de azetidina e usos dos mesmos |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
| GB201311888D0 (en) * | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2015028409A1 (de) | 2013-08-27 | 2015-03-05 | Bayer Pharma Aktiengesellschaft | 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| CA2941161A1 (en) | 2014-03-13 | 2015-09-17 | F.Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
| JP2017507964A (ja) | 2014-03-13 | 2017-03-23 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体モジュレーターを用いた治療的組合せ |
| FI3834824T3 (fi) | 2014-03-28 | 2025-12-05 | Univ Duke | Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla |
| CN107406424B (zh) | 2014-12-18 | 2020-08-25 | 豪夫迈·罗氏有限公司 | 雌激素受体调节剂及其用途 |
| KR102785474B1 (ko) | 2014-12-18 | 2025-03-26 | 에프. 호프만-라 로슈 아게 | 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도 |
| EP3233818A1 (en) | 2014-12-18 | 2017-10-25 | F. Hoffmann-La Roche AG | Derivatives of 2,3-diphenylchromene useful for the treatment of cancer |
| EP3303326B1 (en) | 2015-05-26 | 2020-12-16 | H. Hoffnabb-La Roche Ag | Heterocyclic estrogen receptor modulators and uses thereof |
| KR102710603B1 (ko) | 2015-10-01 | 2024-09-27 | 올레마 파마슈티컬스 인코포레이티드 | 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물 |
| WO2017056115A1 (en) | 2015-10-03 | 2017-04-06 | Sun Pharma Advanced Research Company Limited | Novel n-aryl containing fused heterocyclic compounds |
| US9975856B2 (en) | 2015-10-07 | 2018-05-22 | Genentech, Inc. | Process for the preparation of (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid |
| MX385940B (es) | 2015-10-27 | 2025-03-18 | Sun Pharma Advanced Res Co Ltd | Nuevos antiestrógenos heterocíclicos. |
| SMT202300018T1 (it) | 2015-12-09 | 2023-03-17 | Univ Illinois | Downregolatori del recettore degli estrogeni a base di benzotiofene |
| LT3416962T (lt) | 2016-02-15 | 2021-07-12 | Sanofi | 6,7-dihidro-5h-benzo[7]anuleno dariniai kaip estrogenų recepptoriaus moduliatoriai |
-
2018
- 2018-02-09 KR KR1020197026068A patent/KR20190117582A/ko not_active Withdrawn
- 2018-02-09 JP JP2019542672A patent/JP2020507566A/ja not_active Withdrawn
- 2018-02-09 WO PCT/US2018/017668 patent/WO2018148576A1/en not_active Ceased
- 2018-02-09 EP EP18751944.2A patent/EP3580223A4/en not_active Withdrawn
- 2018-02-09 TW TW107104795A patent/TW201835064A/zh unknown
- 2018-02-09 AU AU2018217809A patent/AU2018217809A1/en not_active Abandoned
- 2018-02-09 CN CN201880020916.XA patent/CN110461853A/zh active Pending
- 2018-02-09 CA CA3052810A patent/CA3052810A1/en not_active Abandoned
- 2018-02-09 US US15/893,295 patent/US10208011B2/en not_active Expired - Fee Related
- 2018-12-14 US US16/221,201 patent/US10633362B2/en not_active Expired - Fee Related
-
2019
- 2019-07-29 IL IL268319A patent/IL268319A/en unknown
-
2020
- 2020-03-19 US US16/824,290 patent/US10981887B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN110461853A (zh) | 2019-11-15 |
| US10981887B2 (en) | 2021-04-20 |
| AU2018217809A1 (en) | 2019-08-22 |
| US10208011B2 (en) | 2019-02-19 |
| KR20190117582A (ko) | 2019-10-16 |
| US20180230123A1 (en) | 2018-08-16 |
| US20190119243A1 (en) | 2019-04-25 |
| US10633362B2 (en) | 2020-04-28 |
| JP2020507566A (ja) | 2020-03-12 |
| TW201835064A (zh) | 2018-10-01 |
| WO2018148576A1 (en) | 2018-08-16 |
| EP3580223A1 (en) | 2019-12-18 |
| EP3580223A4 (en) | 2021-01-06 |
| US20200216406A1 (en) | 2020-07-09 |
| CA3052810A1 (en) | 2018-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285318A (en) | Estrogen receptor modulators | |
| IL268319A (en) | Benzothiophene estrogen receptor modulators | |
| ZA201802901B (en) | Farnesoid x receptor modulators | |
| ZA201605712B (en) | Therapeutic combinations with estrogen receptor modulators | |
| IL274537A (en) | nuclear receptor modulators | |
| IL268263A (en) | Estrogen receptor modulators | |
| SG11201606876RA (en) | Toll like receptor modulator compounds | |
| ZA202000811B (en) | Liquid waste receptor | |
| EP3186225A4 (en) | Cannabinoid type 1 receptor modulators | |
| GB201717974D0 (en) | Modified receptors | |
| IL274322A (en) | Spirocyclic compounds as paranoid X receptor modulators | |
| GB201702617D0 (en) | Receptor | |
| GB201716468D0 (en) | Modulators | |
| IL278045A (en) | History of pyrazo-tetrahydroisoquinoline as a dopamine D1 receptor with positive modulators | |
| ZA201904333B (en) | Adenosine a3 receptor modulators | |
| EP3224230A4 (en) | Estrogen receptor modulators | |
| GB2563095B (en) | Modulators | |
| HK40018940A (en) | Benzothiophene estrogen receptor modulators | |
| GB201701887D0 (en) | Receptor | |
| GB201700926D0 (en) | Receptor | |
| GB201616071D0 (en) | Receptor modulator compounds | |
| GB201616065D0 (en) | Receptor modulator compounds | |
| GB201616072D0 (en) | Receptor modulator compounds | |
| GB201702926D0 (en) | Modulators | |
| GB201512714D0 (en) | Receptor modulator compounds |